Oppenheimer is a buyer of DexCom (DXCM) on weakness from a Bloomberg report on the Apple (AAPL) development program for a non-invasive glucose sensor. Apple’s efforts are not new and the article notes there is "still years of work" ahead, the analyst tells investors in a research note. In addition, the early iteration of Apple’s device was table-top with the goal of development now to create a prototype that would still be about the size of an iPhone that could be strapped to a person’s bicep, the firm points out. Opco assumes a device like this would be more consumer-like with potential use also in pre-diabetes. The firm also sees no impact from the article on continuous glucose monitoring pump partners Insulet (PODD) and Tandem Diabetes (TNDM). The analyst keeps an Outperform rating on DexCom.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DXCM:
- Diabetes management stocks slide on report of tech giant’s breakthroughs
- Apple hits breakthroughs in glucose monitoring project, Bloomberg reports
- DexCom’s G7 receives CMS approval, says Piper Sandler
- DexCom: G7 CGM System to be covered for Medicare beneficiaries
- DexCom price target raised to $110 from $103 at Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue